905587-15-7

Usage

Uses

Used in Pharmaceutical Industry:
S)-1-(5-fluoropyridin-2-yl)ethanaMine is used as a key intermediate in the synthesis of 2-(α-arylalkylamino)-4-(pyrazolylamino)pyrimidines, which are potent inhibitors of Trk kinases. These inhibitors have potential applications in the development of targeted therapies for various cancers, as they can disrupt the signaling pathways involved in tumor growth and progression.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, S)-1-(5-fluoropyridin-2-yl)ethanaMine serves as a valuable building block for the design and synthesis of novel compounds with potential biological activities. Its unique structure and functional groups make it a versatile component in the development of new drugs and therapeutic agents.
Used in Biochemical Evaluation:
S)-1-(5-fluoropyridin-2-yl)ethanaMine plays a crucial role in the biochemical evaluation of Trk kinase inhibitors. It helps researchers understand the structure-activity relationships and optimize the potency and selectivity of these inhibitors, ultimately leading to the discovery of more effective cancer treatments.

Upstream product

• 905587-16-8 (S)-tert-butyl-1-(5-fluoropyridin-2-yl)ethylcarbamate 
• 327056-62-2 5-fluoropicolinonitrile 
• 905587-17-9 (S)-N-(1-(5-fluoropyridin-2-yl)ethyl)acetamide 
• 905587-18-0 N-(1-(5-fluoropyridin-2-yl)vinyl)acetamide 
• 41404-58-4 2-bromo-5-fluoropyridine 
• 915720-56-8 2-(1-azidoethyl)-5-fluoropyridine 
• 915720-55-7 1-(5-fluoropyridin-2-yl)ethanol 
• 915720-54-6 1-(5-fluoropyridin-2-yl)ethan-1-one 
• 915720-57-9 1-(5-fluoropyridin-2-yl)ethan-1-amine 
• 915720-58-0 (1R,2S,5R)-2-isopropyl-5-methylcyclohexyl [(1S)-1-(5-fluoropyridin-2-yl)ethyl]carbamate 

Downstream Products

• 1073149-00-4 (S)-1-(5-fluoropyridin-2-yl)ethanamine hydrochloride 
• 915720-21-7 AZ23 

Relevant academic research and scientific papers

PYRAZOLE DERIVATIVES AS JAK INHIBITORS

New pyrazole derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).

CHEMICAL COMPOUNDS 000-1

The present invention relates to compounds of Formula (I) and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds provide a treatment for myeloproliferative disorders and cancer.

PYRAZOLYL-AMINO-SUBSTITUTED PYRAZINES AND THEIR USE FOR THE TREATMENT OF CANCER

The present invention relates to compounds of Formula (I): and to their pharmaceutical compositions, and to their methods of use. These novel compounds provide a treatment for myeloproliferative disorders and cancer.

5-AMINOPYRAZOL-3-YL-3H-IMIDAZO [4,5-B] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER

The present invention relates to compounds of Formula (I) and to their pharmaceutical compositions, and to their methods of use. These novel compounds provide a treatment for myeloproliferative disorders and cancer.

AMINO-THIAZOLYL- PYRIMIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER

The present invention relates to compounds of Formula (I): and to their pharmaceutical compositions, and to their methods of use. These compounds provide a treatment for myeloproliferative disorders and cancer.

PYRAZOLYL-AMINO-SUBSTITUTED PYRIMIDINES AND THEIR USE FOR THE TREATMENT OF CANCER

The present invention relates to compounds of Formula (I) and to their pharmaceutical compositions, and to their methods of use. These compounds provide a treatment for myeloproliferative disorders and cancer.

Identification of 4-aminopyrazolylpyrimidines as potent inhibitors of Trk kinases

The design, synthesis and biological evaluation of a series of 4-aminopyrazolylpyrimidines as potent Trk kinase inhibitors is reported. High-throughput screening identified a promising hit in the 4- aminopyrazolylpyrimidine chemotype. Initial optimization of the series led to more potent Trk inhibitors. Further optimization using two strategies resulted in significant improvement of physical properties and led to the discovery of 10z (AZ-23), a potent, orally bioavailable Trk A/B inhibitor. The compound offers the potential to test the hypothesis that modulation of Trk activity will be of benefit in the treatment of cancer and other indications in vivo.

Morpholine type cinnamide compound

The present invention relates to a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein R1, R2, R3, and R4 are the same or different and each represent a hydrogen atom or a C1-6 alkyl group; X1 represents a C1-6 alkylene group that may be substituted; Xa represents a methoxy group or a fluorine atom; Xb represents an oxygen atom or a methylene group, provided that Xb is only an oxygen atom when Xa is a methoxy group; and Ar1 represents an aryl group, pyridinyl group, aryloxy group, or pyridinyloxy group that may have a substituent such as a halogen atom; and to use of the compound or salt as a pharmaceutical agent.

CHEMICAL COMPOUNDS

This invention relates to novel compounds having the formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.

PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS

This invention relates to novel compounds having the Formula (I) to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.